SARS-CoV-2 (COVID-19, 2019-nCoV) Reagents

---

---

SARS-CoV-2 (COVID-19) Virus Antibody Research

ProSci Incorporated has developed and manufactured SARS-CoV-2 (COVID-19, 2019-nCoV) antibodies, antigens, and other reagents related to cellular entry: ACE2 receptor, TMPRSSR2 protease, and furin enzyme. ProSci Inc. is continuously adding new SARS-CoV-2 reagents for spike, S1, S2, nucleocapsid, membrane, envelope including llama single domain antibodies and recombinant proteins.

SARS-CoV-2 Featured Products
COVID-19 Patient Validated  Cat. No: 9099 SARS-CoV-2 (COVID-19) Nucleocapsid Antibody Cat. No: 9083 SARS-CoV-2 (COVID-19) Spike S1 Antibody	COVID-19 Patient Validated   Cat. No: 3525 SARS-CoV-2 (COVID-19) Spike Antibody	COVID-19 Patient Validated   Cat. No: 3531 SARS-CoV-2 (COVID-19) Envelope Antibody

---

SARS-CoV-2 (COVID-19) Antibody Pairs

ProSci Incorporated has launched matched SARS-CoV-2 (COVID-19, 2019-nCoV) antibody pairs validated by sandwich ELISA. These spike antibody pair and nucleocapsid antibody pairs are suitable for COVID-19 antigen test, ELISA, lateral flow and other immunoassay.

SARS-CoV-2 Nucleocapsid Matched Pair Antibodies

Pair	Capture Ab.	Host	Clonality	Detection Ab.	Host	Clonality	Target Protein	Binding Protein
1	35-720	Mouse	Monoclonal	9103	Rabbit	Polyclonal	Nucleocapsid	10-306
2	10-352	Rabbit	Monoclonal	35-719	Mouse	Monoclonal	Nucleocapsid	10-306
3	10-352	Rabbit	Monoclonal	35-720	Mouse	Monoclonal	Nucleocapsid	10-306

SARS-CoV-2 Spike Matched Pair Antibodies

Pair	Capture Ab.	Host	Clonality	Detection Ab.	Host	Clonality	Target Protein	Binding Protein
1	10-351	Rabbit	Monoclonal	10-706	Human	Monoclonal	Spike	97-087
2	10-351	Rabbit	Monoclonal	9083-biotin	Rabbit	Polyclonal	Spike	97-087
3	10-351	Rabbit	Monoclonal	9091-biotin	Rabbit	Polyclonal	Spike	97-087

---

New Product Pipeline for SARS-CoV-2

ProSci Incorporated continues to develop more SARS-CoV-2 (COVID-19, 2019-nCoV) antibodies and proteins against the full proteome of SARS-CoV-2, including Envelop, Matrix, NSPs and ORFs, which will be launched soon.

Ab Target	SARS-CoV-2	Release Date
Envelope	9169	Released
Membrane	9157, 9167	Released
3CL-P/NSP5	9151, 9153	Released
NSP7	9155	Released
NSP8	9159, 9167	Released
NSP9	9161, 9163	Released
NSP2	9171, 9173	Released
NSP4	9175	Released
NSP6	9177	Released
NSP10	9179	Released
NSP13	9181, 9183	Released
NSP14	9185, 9187	Released
ORF6	9189	Released
ORF9b	9191	Released
ORF7b		12/20/2020
NSP11		12/20/2020
NSP12		12/20/2020
NSP15		12/20/2020
NSP16		12/20/2020

---

SARS-CoV-2 (COVID-19, 2019-nCoV) Antibody Reagents

ProSci offers a comprehensive list of SARS-CoV-2 antibodies against viral proteins; spike, nucleocapsid, envelope, ORF, and NSP. These antibodies can be used with various applications: IHC, Flow Cytometry, ELISA, WB, and Lateral-Flow.

Diagram of SARS-CoV-2 with Validated Antibodies

Target SARS-CoV-2 Structure Protein Antibodies Spike S1 9083 / 9091 / 10-350 / 10-351 / 10-703 / 10-706 / ... Spike RBD 9087 / 93-309 / 10-713 / 10-715 / 10-052 / 10-059 / ... Spike S2 3525 / 9123 / 9119 Spike ECD 24-032 / 10-528 / 10-534 Nucleocapsid 9099 / 9103 / 35-579 / 35-719 / 10-352 / 10-353 / ... Envelope 3531 / 9169 / 10-518 Membrane 9165 / 9157 / 10-516

Diagram of ProSci Inc. Antibodies against SARS-CoV-2 Proteome

Target SARS-CoV-2 ORF/NSP Antibodies ORF3a 10-519 / 10-520 / 10-521 / 10-533 ORF6 9189 / 10-515 ORF7a 10-513 / 10-514 ORF8 10-511 / 10-512 / 10-532 ORF9b 9191 ORF10 10-507 NSP1 10-500 NSP2 9171, 9173 PPL-P/NSP3 10-504 / 10-505 / 10-506 NSP4 9175 3CL-P/NSP5 9151, 9153

Target SARS-CoV-2 NSP Antibodies NSP6 9177 NSP7 9155 NSP8 9159, 9167 NSP9 9161, 9163 NSP10 9179 NSP12 Soon to be released NSP13 9181, 9183 NSP14 9185, 9187 NSP15 Soon to be released NSP16 Soon to be released

---

SARS-CoV-2 (COVID-19, 2019-nCoV) Recombinant Protein

Recombinant proteins developed in-house & tested with validated antibodies. Our recombinant proteins expressed are in various cell lines and expression systems for the novel coronavirus SARS-CoV-2 (COVID-19, 2019-nCoV): Full/partial length, tagged/untagged, and biologically active.

Diagram of SARS-CoV-2 Proteins

Target SARS-CoV-2 Structure Protein Spike S1 10-422 / 10-423 / 97-087 / ... Spike RBD 10-303 / 10-433 / 97-093 / ... Spike S2 10-426 / 10-115 Spike ECD 10-108 / 10-121 / 10-122 Nucleocapsid 10-306 / 10-434 / 97-082 / ... Envelope 10-112 / 97-082 Membrane 10-429

Diagram of ProSci Inc. Proteins against SARS-CoV-2 Proteome

Target SARS-CoV-2 ORF/NSP Protein ORF3a 10-005 ORF6 10-437 ORF7a 10-435 ORF8 10-002 / 10-436 NSP1 10-416 / 97-095 NSP2 10-425 PPL-P/NSP3 10-404 / 10-406 / 10-119 3CL-P/NSP5 10-400 / 10-412 / 10-116

Target SARS-CoV-2 NSP Protein NSP7 97-096 NSP8 10-415 / 97-097 NSP9 10-417 NSP10 10-408 NSP12 10-419 NSP13 10-427 NSP15 10-420 NSP16 10-418

---

SARS-CoV Reagents

In addition to our coronavirus COVID-19 (SARS-CoV-2) antibodies & recombinant proteins, similar related reagents are available for SARS-CoV.  The two viruses, SARS-CoV-2 and SARS-CoV, have approximately 79% sequence identity. For potential antibody cross reactivity refer to the table below.   

ProSci Inc. SARS-CoV Antibodies Diagram

SARS-CoV Antibodies

Product	Cat. No.	Host	Application	Clonality	Protein Structure	Identity	Homology	Blocking Peptide
SARS Spike Antibody	3221	Rabbit	ELISA	Polyclonal	Spike Protein	56%	69%	Blocking Peptide
SARS Spike Antibody	3225	Rabbit	ELISA	Polyclonal	Spike Protein	38%	56%	Blocking Peptide
SARS Spike Antibody	3219	Rabbit	ELISA	Polyclonal	Spike Protein	14%	29%	Blocking Peptide
SARS Matrix Antibody	3527	Rabbit	ELISA	Polyclonal	Membrane Protein	86%	93%	Blocking Peptide
SARS Matrix Antibody	3529	Rabbit	ELISA	Polyclonal	Membrane Protein	80%	93%	Blocking Peptide
SARS Envelope Antibody	3533	Rabbit	ELISA	Polyclonal	Envelope Protein	82%	91%	Blocking Peptide

SARS-CoV Recombinant Protein

Product	Cat. No.	Source	Fusion Tag	Sequence
SARS S Recombinant Protein	97-094	HEK293	His Tag	Ser 14 - Pro 1195

    

For COVID-19 (SARS-CoV-2) receptor reagents, check out our ACE2 products! In addition to all our COVID-19 related antibody reagents, we also offer custom antibody services for polyclonal, monoclonal, and single domain antibodies.

---

What is SARS-CoV-2?

SARS-CoV-2 (COVID-19, 2019-nCoV) is a major public heatlh threat with more than 1,200,000 deaths worldwide. The first stage in the coronavirus life cycle is viral entry where the viral spike protein will bind to a specific cell surface receptor. The spike proteins of SARS-CoV-2, as well as SARS-CoV-1 and NL63 use angiotensin-converting enzyme 2 (ACE2) as a receptor for binding. An antibody for this ACE2 protein has been produced by ProSci Inc. (Catalog No. 3217) that has been shown to function in immunohistochemistry and immunofluorescence experiments in human samples, and western blot experiments in human, mouse, and rat samples.

SARS-CoV-2 (COVID-19, 2019-nCoV) Background

COVID-19 is an acute respiratory disease caused by novel coronavirus SARS-CoV-2  also known as 2019-nCoV. On March 11, 2020, the World Health Organization (WHO) characterized COVID-19 as a pandemic[i]. COVID-19 coronavirus SARS-CoV-2 belongs to the Betacoronavirus genus originating from bats. Betacoronaviruses can infect mammals, are zoonotic pathogens, and can cause severe respiratory disease in humans. Other viruses in this family are SARS coronavirus and MERS coronavirus. COVID-19 (SARS-CoV-2) has approximately 79% sequence identity to SARS-CoV and 50% to MERS-CoV.[ii] In addition, homology modeling shows COVID-19 (SARS-CoV-2)  has a similar receptor-binding domain structure as SARS-CoV which suggests SARS-CoV-2 uses ACE2 receptor in humans for infection.  

SARS-CoV-2 (COVID-19, 2019-nCoV) Structure

The structure[iii] of COVID-19 (SARS-CoV-2) consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E), a nucleocapsid protein (N), and RNA as seen in the figure below.

Spike protein (S) is heavily glycosylated, utilizes an N-terminal signal sequence to gain access to the ER and mediate attachment to host receptors. It is the largest structure and makes the distinct spikes on the surface of the virus. For SARS-CoV-2, S protein is cleaved by cellular furin-like protease TMPRSS2[iv] into two separate polypeptides S1 and S2. S1 also consists of a receptor binding domain(RBD) which binds to virus receptor ACE2 RNA is the genome of the virus. Nucleocapsid protein (N) binds to RNA in vitro and is heavily phosphorylated. N proteins binds the viral genome in a beads on a string type conformation. This protein likely helps tether the viral genome to replicase-transcriptase complex (RTC), and subsequently package the encapsulated genome into viral particles. Envelope protein (E) is found in small quantities in within the virus. It is most likely a transmembrane protein and with ion channel activity. The protein facilitates assembly and release of the virus and has other functions such as ion channel activity. It is not necessary for viral replication but it is for pathogenesis.  Membrane protein (M) is the most abundant structural protein. It does not contain signal sequence and exists as a dimer in the virion. It may have two different conformations to enable it to promote membrane curvature as well as bind to nucleocapsid. Hemagglutinin-esterase dimer protein (HE) is present in a subset of betacoronaviruses. The protein binds sialic acids on surface glycoproteins. The protein activities are thought to enhance S protein-mediated cell entry and virus spread through the mucosa.